Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets.
RNA interference (RNAi) provides a powerful means of sequence-specific gene silencing. Several studies show that RNAi may provide promising strategies to treat human diseases by suppressing disease responsible genes in vivo. In locomotor diseases, the progression of collagen-induced arthritis (CIA) is suppressed by tumor necrosis factor-alpha (TNF-alpha)-specific small interfering RNA (siRNA) delivered into the joint. The aim of this study, is to compare the effects of intraarticularly administered siRNAs targeting TNF-alpha, interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and receptor activator of NF-kappaB ligand (RANKL) on CIA in rats. We confirmed that the silencing effects of siRNA duplexes specific for rat TNF-alpha, IL-1beta, IL-6 and RANKL in vitro. Each siRNA was also delivered into the knee joint of CIA rats by the in vivo electroporation method 7, 10, 13 and 16 days after immunization with collagen. Local delivery of TNF-alpha or IL-1beta-specific siRNA ameliorated CIA in rats effectively at the gross morphological, radiographical and histological evaluations. Our results suggested that TNF-alpha and IL-1beta were the cytokines to be targeted in the joint for the treatment of rheumatoid arthritis. The in vivo siRNA transfection method may be useful for selection of target molecules to be silenced for treatment of joint diseases.
Inoue
Atsuo
A
Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Takahashi
Kenji A
KA
Mazda
Osam
O
Arai
Yuji
Y
Saito
Masazumi
M
Kishida
Tsunao
T
Shin-Ya
Masaharu
M
Morihara
Toru
T
Tonomura
Hitoshi
H
Sakao
Kei
K
Imanishi
Jiro
J
Kubo
Toshikazu
T
D000818:Animals; D000843:Ankle Joint / Q000473:pathology; D018501:Antirheumatic Agents; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D003094:Collagen; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000235:genetics; D005528:Foot / Q000000981:diagnostic imaging; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000235:genetics; D015850:Interleukin-6 / Q000235:genetics; D053245:RANK Ligand / Q000037:antagonists & inhibitors / Q000235:genetics; D034622:RNA Interference; D034741:RNA, Small Interfering; D011859:Radiography; D051381:Rats; D013582:Synovial Fluid / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000235:genetics; D000093242:Interleukin-6 Inhibitors
D018501:Antirheumatic Agents; D003094:Collagen; D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D053245:RANK Ligand; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors